Search Results
Your search for all items matches 34748 pages
Showing 9951 - 10000Study Identifies Mechanisms Tied to Immunotherapy Resistance Among Patients With Melanoma
Researchers have created a new technique that may help to uncover mechanisms cancer cells use to evade immunotherapies, which could lead to the development of more effective treatments. Investigators tested their new technique with cancer cells and matching immune cells from patients with melanoma...
Effect of Clinical Breast Examination Screening on Stage at Diagnosis and Breast Cancer Mortality
In an Indian study reported in the British Medical Journal, Mittra et al found that breast cancer screening with clinical breast examination vs active surveillance resulted in younger age and significant downstaging of disease at diagnosis of breast cancer, a significant reduction in breast cancer...
Long-Term Follow-up of Adjuvant Imatinib for Localized Gastrointestinal Stromal Tumors
Final analysis of a collaborative intergroup study confirmed the efficacy of adjuvant treatment with imatinib in patients with localized gastrointestinal stromal tumor (GIST) in terms of prolonged relapse-free survival. In the high-risk subgroup, there was a trend toward a better long-term imatinib ...
Mental Health Service Use Among Testicular Cancer Survivors
In a Canadian population-based cohort study reported in the Journal of Clinical Oncology, Raphael et al found that survivors of testicular cancer were more likely to use mental health services in both the short and long term following treatment compared with the general population. Study Details...
UN Human Rights Experts Comment on Environmental Racism in Louisiana’s ‘Cancer Alley’
“Cancer Alley,” located in Louisiana along the lower Mississippi River, serves as an industrial hub, with nearly 150 oil refineries, plastics plants, and chemical facilities. The ever-widening corridor of petrochemical plants has not only polluted the surrounding water and air, but also subjected...
FDA Approves Lorlatinib for Metastatic ALK-Positive NSCLC
On March 3, the U.S. Food and Drug Administration (FDA) granted regular approval to lorlatinib (Lorbrena) for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test. The FDA also approved the...
Preclinical Research Shows Activity of Fidaxomicin Combination Therapy in MLL-AML
A specific type of acute myeloid leukemia (AML) that contains a rearrangement in the MLL gene (also known as KMT2A) might be made more sensitive to chemotherapy using an antibiotic currently available to treat diarrhea, according to new research published by Zeisig et al in Science Translational...
Recent Study Examines Potential New Therapies, Assessment of Biomarkers in Endometrial Cancer
In a new study published by Merritt et al in Cancer Epidemiology, Biomarkers & Prevention, researchers demonstrated that sex hormones and insulin growth factors may be associated with recurrence risk in patients with endometrial cancer. The findings suggest endocrine-targeted therapies and an...
Study Finds Missing Annual Mammogram Increases Risk of Death From Breast Cancer
Regular mammography screening substantially reduces the risk of dying from breast cancer, according to a large study of over half a million women published by Stephen W. Duffy, MSc, and colleagues in the journal Radiology. Researchers said women who skipped even one scheduled mammography screening...
Bipolar Androgen Therapy vs Enzalutamide in Asymptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
In the phase II TRANSFORMER trial reported in the Journal of Clinical Oncology, Denmeade et al found no difference in progression-free survival with bipolar androgen therapy—defined as rapid cycling between high and low serum testosterone—vs enzalutamide in men with metastatic castration-resistant...
Five-Year Outcomes With Tisagenlecleucel in Patients With Relapsed or Refractory B-Cell Lymphomas
As reported in a letter to the editor in The New England Journal of Medicine by Elise A. Chong, MD, and colleagues, long-term follow-up of a single-center trial of tisagenlecleucel showed maintained responses in a high proportion of patients with relapsed or refractory diffuse large B-cell lymphoma ...
Study Examines Extrapleural Pneumonectomy After IMRT for Malignant Pleural Mesothelioma
In a Canadian single-center phase II feasibility study reported in The Lancet Oncology, Cho et al found that a treatment protocol (surgery for mesothelioma after radiotherapy, also known as SMART) consisting of hemithoracic intensity-modulated radiotherapy (IMRT) followed by extrapleural...
Pembrolizumab's Indication in Small Cell Lung Cancer Is Withdrawn
On March 1, Merck announced the company is voluntarily withdrawing the U.S. indication for pembrolizumab (Keytruda) for the treatment of patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. The ...
Anti-CD20 Monoclonal Antibodies and Risk of Severe COVID-19 Infection and Death in Patients With Lymphoma
Patients with lymphoma hospitalized for severe COVID-19 infection were at higher risk for prolonged hospital stay and death if they were treated with B-cell–depleting therapies (eg, rituximab, obinutuzumab) within the previous 12 months. The risk of persistent COVID-19 infection was also higher in...
Machine Learning Algorithm Is Successful in Predicting Malignancy in Patients With Multiple Pulmonary Nodules
Although guidelines exist for the use of several clinical prediction models based on logistic regression to help estimate the risk of lung cancer before treatment decision-making, they almost all focus on solitary pulmonary nodules, and have not shown accuracy in predicting malignancy in multiple...
ASCO’s Road to Recovery Report Outlines Lessons Learned From the COVID-19 Pandemic to Improve Oncology Care
In 2020, ASCO established the Steering Group on Cancer Care Delivery and Research in a Post-Pandemic Environment to evaluate the changes made in oncology care delivery, clinical research, and regulatory oversight in response to the COVID-19 pandemic as well as to make recommendations on how to...
SWOG 1500: Cabozantinib, Crizotinib, or Savolitinib vs Sunitinib in Metastatic Papillary Renal Cell Carcinoma
In the phase II SWOG 1500 study reported in The Lancet, Pal et al found that among three comparator MET kinase inhibitors, cabozantinib prolonged progression-free survival vs sunitinib in metastatic papillary renal cell carcinoma. Study Details In the open-label trial, 147 eligible patients from...
CLEAR Trial: Is Lenvatinib Plus Pembrolizumab the Best First-Line Immunotherapy Doublet in Metastatic Renal Cell Carcinoma?
At the 2021 Genitourinary Cancers Symposium, Motzer et al presented the clinical results of the CLEAR trial, adding a novel regimen, lenvatinib plus pembrolizu-mab, to the growing armamentarium of first-line treatments for patients with metastatic clear cell renal cell carcinoma (RCC). The...
FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine
On February 27, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the third vaccine for the prevention of COVID-19. The EUA allows the Janssen COVID-19 Vaccine to be distributed in the United States for use in individuals 18 years of age and older. The FDA...
FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma
On February 26, the U.S. Food and Drug Administration (FDA) granted accelerated approval to melphalan flufenamide (Pepaxto) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is...
Enfortumab Vedotin-ejfv in Previously Treated Advanced Urothelial Carcinoma
As reported in The New England Journal of Medicine by Powles et al, a prespecified interim analysis of the phase III EV-301 trial has shown improved overall survival with enfortumab vedotin-ejfv vs investigator choice of chemotherapy in patients with previously treated advanced urothelial...
EMPOWER-Lung 1: First-Line Cemiplimab-rwlc vs Platinum-Doublet Chemotherapy in Advanced NSCLC With PD-L1 Expression ≥ 50%
As reported in The Lancet by Sezer et al, the phase III EMPOWER-Lung 1 trial has shown improved overall and progression-free survival with cemiplimab-rwlc vs platinum doublet chemotherapy among patients with advanced non–small cell lung cancer (NSCLC) with PD-L1 expression on ≥ 50% of tumor cells...
Updates From Selected Clinical Trials in Breast Cancer
Each year, following the San Antonio Breast Cancer Symposium (SABCS), The ASCO Post asks Jame Abraham, MD, FACP, to offer his picks of the most important and most clinically relevant research presented at this meeting. The following are summaries of studies that caught Dr. Abraham’s attention from ...
PHOEBE Trial: Pyrotinib/Capecitabine vs Lapatinib/Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab
In a prespecified interim analysis of the Chinese phase III PHOEBE trial reported in The Lancet Oncology, Xu et al found that the combination of the irreversible pan-HER inhibitor pyrotinib plus capecitabine significantly prolonged progression-free survival vs lapatinib plus capecitabine in...
The Impact of a Pandemic on Mentorship in Medicine
When advising the younger members of our medical community on career decisions, I always list “access to the best mentorship” as the most important priority. By the time we hit residency, we have all proven ourselves able to extract from a book or a journal the facts essential to the practice of...
Expert Point of View: Michael Overman, MD
At the 2021 Gastrointestinal Cancers Symposium, the KEYNOTE-177 investigators updated their previously reported findings by showing further data relating to subsequent lines of therapy after disease progression. Their conclusion was that patients who received pembrolizumab initially still achieved...
KEYNOTE-177: New Analysis Confirms Benefit of Pembrolizumab vs Chemotherapy in Microsatellite Instability–High Advanced Colorectal Cancer
In an updated analysis of the pivotal phase III KEYNOTE-177 trial in microsatellite instability–high (MSI-H) metastatic colorectal cancer, the benefit of first-line pembrolizumab continued beyond disease progression on the subsequent line of treatment, despite a high crossover to immunotherapy for...
Genitourinary Cancers Symposium: Immunotherapy for RCC, Neoadjuvant Therapy for Bladder Cancer
This week, we’re continuing our coverage of results presented at the 2021 Genitourinary Cancers Symposium, focusing on research findings in renal cell carcinoma (RCC) and bladder cancer.
Tracy L. Rose, MD, on Bladder Cancer: Gemcitabine, Cisplatin, and Pembrolizumab as Neoadjuvant Therapy
Tracy L. Rose, MD, of the University of North Carolina at Chapel Hill, discusses phase II results of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy for patients with muscle-invasive bladder cancer. The trial showed this combination...
KEYNOTE-427: First-Line Pembrolizumab in Advanced Non–Clear Cell Renal Cell Carcinoma
As reported in the Journal of Clinical Oncology by McDermott et al, findings in a cohort of the phase II KEYNOTE-427 study showed that pembrolizumab monotherapy produced durable responses as first-line treatment for advanced non–clear cell renal cell carcinoma. In a separate cohort of the study,...
Endoscopic Nasopharyngectomy vs IMRT for Previously Treated, Resectable, Locally Recurrent Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in The Lancet Oncology, Liu et al found that endoscopic nasopharyngectomy was associated with improved overall survival vs intensity-modulated radiotherapy (IMRT) in patients with resectable locally recurrent nasopharyngeal carcinoma who had received prior...
LuPSMA Leads to Improved PSA Response, Fewer Severe Adverse Events Than Cabazitaxel in Patients With Metastatic Prostate Cancer
In the Australian phase II trial TheraP reported in The Lancet, Michael S. Hofman, FRACP, MBBS, and colleagues found that Lutetium-177–labeled PSMA-617 (LuPSMA) treatment was associated with a higher prostate-specific antigen (PSA) response rate and fewer severe adverse events vs cabazitaxel in...
New Report Reviews Methods for Reducing Waste, Improving Efficiency With Expensive Injectable Medications
Every year, significant amounts of drugs left over and unused from single-dose vials are discarded, but because of the way drugs are priced and paid for in the United States, the cost of the discarded amount cannot be recouped, according to a new congressionally mandated report from the National...
Elizabeth R. Plimack, MD, on Bladder Cancer Highlights From the 2021 Genitourinary Cancers Symposium
Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses key abstracts discussed at this year’s meeting on bladder cancer and offers her views on the latest trends and findings (Abstracts 391, 393, 434).
Biden Administration, New Congress Review Recent Rules Affecting Cancer Care Delivery
In the days and weeks leading up to President Biden’s inauguration, the Department of Health and Human Services (HHS)—under the prior administration—issued a number of rules and regulations that affect cancer care delivery. Many of those rules and regulations are now subject to review by the new...
Medicare Physician Fee Schedule Conversion Factor Updated to Reflect 2021 Federal Funding Package
The Centers for Medicare & Medicaid Services (CMS) announced a revised Medicare Physician Fee Schedule conversion factor of $34.8931 for 2021. This represents a 3.3% reduction from the 2020 conversion factor of $36.0869. CMS updated the conversion factor as a result of a provision in the $1.4...
Standardized, Streamlined Processes Key to Implementing Electronic Prior Authorization
On December 23, 2020, ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to the Reducing Provider and Patient Burden and Promoting Patients’ Electronic Access to Health Information proposed rule. This rule builds on the CMS Interoperability and Patient...
New Framework to Address Cancer Care Disparities in Medically Underserved Populations
A new article published in JCO Oncology Practice puts forth a framework to guide researchers, health-care leaders, advocates, community- and patient-focused service organizations, and policy leaders in their work to address and promote health equity in cancer care access and treatment outcomes.1...
ASCO Names Advance of the Year: Molecular Profiling Drives Progress in Gastrointestinal Cancers
Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal cancers. In...
In Case You Missed It: Brief Highlights From ASH 2020
In case you missed these while attending the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, below is a sampler of highlights that were not included in our first round of meeting coverage. Many of these reports are on early-phase clinical trials of agents that may raise...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Kenya
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Kenya. The aim of this special feature is to highlight the global cancer burden for various countries of the...
Expert Point of View: Lucia Masarova, MD
Lucia Masarova, MD, Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, said the updated long-term data for momelotinib show “durable efficacy and exciting outcomes” in patients with myelofibrosis, regardless of prior exposure to...
SIMPLIFY Trials: JAK Inhibitor Yields Long-Term Survival Benefit and Transfusion Independence in Myelofibrosis
Treatment with the novel JAK inhibitor momelotinib led to long-term overall survival and sustained transfusion independence in patients with intermediate- or high-risk myelofibrosis, according to updates from the SIMPLIFY-1 and SIMPLIFY-2 trials presented at the 2020 American Society of Hematology...
I Let Science, Not Emotion, Dictate My Treatment
I had my first experience with cancer when I was just 3 or 4 years old and complained to my mother that my “tummy hurt.” I was diagnosed with Wilms tumor, the same cancer my 18-month-old brother died of before I was born. I remember being in the hospital for weeks at a time and being known by...
Paul A. Bunn, Jr, Scientific Award Presented to Joan H. Schiller, MD, FASCO
Joan H. Schiller, MD, FASCO, was recently honored by the International Association for the Study of Lung Cancer (IASLC) with the Paul A. Bunn, Jr, Scientific Award. Dr. Schiller’s many accomplishments include helping to break the taboo of talking about lung cancer and expanding public...
Crystal Denlinger, MD, FACP, Named Chief Scientific Officer for NCCN
The National Comprehensive Cancer Network© (NCCN) recently announced the appointment of Crystal S. Denlinger, MD, FACP, to the newly created role of Senior Vice President, Chief Scientific Officer. In this position, Dr. Denlinger will help to steer strategic direction for the nonprofit as well as...
IASLC Honors Pan-Chyr Yang, MD, PhD, for Contributions to Lung Cancer Prevention
Pan-Chyr Yang, MD, PhD, Chair Professor at the National Taiwan University Hospital and Academician of Academia Sinica, Taiwan, received the Joseph W. Cullen Prevention/Early Detection Award from the International Association for the Study of Lung Cancer (IASLC) at the virtual IASLC 2020 World...
Expert Point of View: Yun Fan, MD, and Deborah Doroshow, MD, PhD
Invited discussant of KEYNOTE-598,1Yun Fan, MD, Director of Thoracic Tumor Center at Zhejiang Cancer Hospital in Hangzhou, China, suggested that patients with non–small cell lung cancer (NSCLC) with low PD-L1 expression and those with high tumor mutational burden may, in fact, derive the most...
When to Start a Conversation With Patients About Subsequent Primary Cancers
Among patients who survive a primary cancer, concern about recurrence, especially metastatic disease, is extremely common; however, information about future risk for subsequent primary cancers is seldom communicated to these patients, leading to missed opportunities to prevent or detect subsequent...
Ongoing Surveillance and Efforts to Reduce Smoking and Obesity Needed to Lower Cancer Survivors’ Risks of New Cancers
The risk of developing or dying of a new primary cancer, particularly those cancers associated with smoking and obesity, was greater among survivors of adult-onset cancers than the expected risk in the general population, according to an analysis of data from more than 1.5 million cancer...
